Amphastar Pharmaceuticals is rated a Buy, with ~81% upside to a $33 fair value, despite margin pressures for 2026. AMPH faces declining sales in legacy products but expects mid- to high-single-digit ...

David is comprehensively experienced in many facets of financial and legal research and publishing. As an Investopedia fact checker since 2020, he has validated over 1,100 articles on a wide range of ...

Overlay Shares implements the strategy through put spreads, pairing each short put with a lower-strike long put to establish a defined-risk options overlay. For some investors, selling puts may offer ...

For years, advanced options strategies—like out-of-the-money puts—occupied a narrow slice of the market, largely confined to clients with $50 million or more and the infrastructure to support them.

While many investors view options trading as a short-term strategy, it can also play an important role in a long-term ...

Volatility and option premiums move together. When India VIX falls, premiums shrink. For option buyers, that is bad news. For ...